← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

PureTech Health plc (PRTC) 10-Year Financial Performance & Capital Metrics

PRTC • • Industrial / General
HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders
AboutPureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Show more
  • Revenue $5M +45.0%
  • EBITDA -$133M +6.2%
  • Net Income $54M +181.4%
  • EPS (Diluted) 2.00 +183.3%
  • Gross Margin 26.04% +154.1%
  • EBITDA Margin -2744.9% +35.3%
  • Operating Margin -2818.87% +35.8%
  • Net Margin 1108.33% +156.2%
  • ROE 12.36% +194.6%
  • ROIC -46.17% -55.2%
  • Debt/Equity 0.05 -0.9%
  • Interest Coverage -13.56 -25.1%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Share count reduced 2.4% through buybacks
  • ✓Trading at only 1.3x book value

✗Weaknesses

  • ✗Profits declining 33.8% over 5 years
  • ✗Negative free cash flow
  • ✗Sales declining 11.1% over 5 years
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.15%
5Y-11.09%
3Y-21.5%
TTM-79.43%

Profit (Net Income) CAGR

10Y-
5Y-33.81%
3Y-
TTM48.81%

EPS CAGR

10Y-
5Y-32.62%
3Y-
TTM40.91%

ROCE

10Y Avg-45.34%
5Y Avg-22.07%
3Y Avg-25.29%
Latest-22.61%

Peer Comparison

Psychiatric & CNS Disorders
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
ACADACADIA Pharmaceuticals Inc.4.54B26.8619.7531.85%24.94%28.47%3.46%0.07
JAZZJazz Pharmaceuticals plc10.38B170.8119.756.12%-8.86%-9.31%12.99%1.51
CPRXCatalyst Pharmaceuticals, Inc.2.85B23.1717.6923.49%37.63%23.64%8.4%0.00
HRMYHarmony Biosciences Holdings, Inc.2.08B36.0414.3622.8%22.48%22.23%10.53%0.28
ALKSAlkermes plc5.06B30.6214.11-6.36%22.27%19.55%8.02%0.05
PRTCPureTech Health plc458.47M18.979.4944.98%-495.91%-8.53%0.05
LBRXLB Pharmaceuticals Inc Common Stock489.79M19.36-1.09
NMRANeumora Therapeutics, Inc. Common Stock365.37M2.15-1.41-178.79%0.01

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+11.74M4.43M650K16.37M8.69M8.34M9.98M2.09M3.33M4.83M
Revenue Growth %4.83%-0.62%-0.85%24.19%-0.47%-0.04%0.2%-0.79%0.59%0.45%
Cost of Goods Sold+740K1.57M71.03M77.4M85.85M0110.47M152.43M4.93M0
COGS % of Revenue0.06%0.35%109.28%4.73%9.88%-11.07%72.93%1.48%-
Gross Profit+11M2.86M-70.39M-61.03M-77.16M8.34M-100.49M-136.81M-1.6M1.26M
Gross Margin %0.94%0.65%-108.28%-3.73%-8.88%1%-10.07%-65.46%-0.48%0.26%
Gross Profit Growth %4.47%-0.74%-25.6%0.13%-0.26%1.11%-13.05%-0.36%0.99%1.78%
Operating Expenses+55.38M78.36M116.07M120.39M144.09M127.87M160.26M60.99M54.55M140.41M
OpEx % of Revenue4.72%17.68%178.57%7.35%16.58%15.33%16.06%29.18%16.38%29.08%
Selling, General & Admin18.38M37.16M46.28M24.43M34.89M26.5M30.76M35.67M48.36M27.49M
SG&A % of Revenue1.57%8.39%71.2%1.49%4.02%3.18%3.08%17.07%14.52%5.69%
Research & Development13.41M41.2M71.67M57.29M65.17M61.19M81.52M116.11M96.23M54.28M
R&D % of Revenue1.14%9.3%110.26%3.5%7.5%7.34%8.17%55.56%28.9%11.24%
Other Operating Expenses448K46K14K-278K44.03M40.19M47.98M-90.79M-90.04M58.64M
Operating Income+-43.64M-73.93M-115.42M-104.02M-135.4M-119.53M-150.28M-197.81M-146.2M-136.09M
Operating Margin %-3.72%-16.68%-177.57%-6.35%-15.58%-14.33%-15.06%-94.64%-43.9%-28.19%
Operating Income Growth %-1.5%-0.69%-0.56%0.1%-0.3%0.12%-0.26%-0.32%0.26%0.07%
EBITDA+-42.9M-72.36M-113.32M-101.24M-128.73M-112.88M-143.04M-188.91M-141.27M-132.52M
EBITDA Margin %-3.65%-16.33%-174.34%-6.18%-14.82%-13.53%-14.33%-90.39%-42.42%-27.45%
EBITDA Growth %-1.53%-0.69%-0.57%0.11%-0.27%0.12%-0.27%-0.32%0.25%0.06%
D&A (Non-Cash Add-back)740K1.57M2.1M2.78M6.67M6.66M7.24M8.89M4.93M3.57M
EBIT-51.97M-76.37M-70.01M-68.05M481.12M56.03M19.46M-197.81M-16.56M33.81M
Net Interest Income+-4.09M-5.62M-8.46M-11.45M260K-1.76M-4.5M1.85M2.52M12.63M
Interest Income262K1.19M1.75M3.36M4.36M1.18M214K5.8M16.01M22.67M
Interest Expense4.35M6.81M10.21M14.81M4.1M2.95M4.71M3.95M13.49M10.04M
Other Income/Expense-12.68M-9.25M44.71M35.58M613.87M138.5M91.33M105.02M110.1M159.87M
Pretax Income+-56.32M-83.18M-70.71M-68.44M478.47M18.97M-58.95M-92.78M-36.1M23.77M
Pretax Margin %-4.8%-18.77%-108.79%-4.18%55.07%2.27%-5.91%-44.39%-10.84%4.92%
Income Tax+1.92M-1.57M-14K2.22M112.41M14.4M3.76M-55.72M30.52M-4.01M
Effective Tax Rate %0.7%0.59%-0.44%0.64%0.88%0.32%1.03%0.54%1.82%2.25%
Net Income+-39.39M-48.79M30.87M-43.65M421.14M5.99M-60.56M-50.35M-65.7M53.51M
Net Margin %-3.36%-11.01%47.49%-2.67%48.47%0.72%-6.07%-24.09%-19.73%11.08%
Net Income Growth %0.05%-0.24%1.63%-2.41%10.65%-0.99%-11.12%0.17%-0.3%1.81%
Net Income (Continuing)-58.24M-81.61M-57.49M-70.66M335.27M4.57M-62.71M-37.06M-66.63M27.78M
Discontinued Operations0000000000
Minority Interest-62.07M-85.25M-150.31M-108.53M-17.64M-16.21M-9.37M5.37M-5.83M-6.77M
EPS (Diluted)+-2.10-2.101.10-1.6014.400.20-2.10-1.80-2.402.00
EPS Growth %0.59%0%1.52%-2.45%10%-0.99%-11.5%0.14%-0.33%1.83%
EPS (Basic)-2.10-2.101.10-1.6014.900.20-2.10-1.80-2.402.00
Diluted Shares Outstanding18.53M22.95M23.89M27.38M29.18M29.29M28.66M28.48M27.63M26.97M
Basic Shares Outstanding18.53M22.95M24.07M27.28M29.25M29.93M28.66M27.97M27.63M26.97M
Dividend Payout Ratio--0%-0%-----

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+318.2M288.15M198.11M259.79M168.84M414.35M501.81M386.19M347.2M386.26M
Cash & Short-Term Investments314.53M282.37M189.67M250.88M162.45M403.88M465.71M350.1M327.14M367.31M
Cash Only134.75M62.96M72.65M117.05M132.36M403.88M465.71M149.87M191.08M280.64M
Short-Term Investments179.78M219.41M117.03M133.83M30.09M00200.23M136.06M86.67M
Accounts Receivable706K125K1.8M1.33M2.33M2.94M3.59M22.36M2.38M12.9M
Days Sales Outstanding21.9510.31.01K29.6197.76128.61131.273.9K260.43975.48
Inventory0-1.92M-2.72M-1.33M0028M000
Days Inventory Outstanding------92.51---
Other Current Assets896K897K927K2.2M2.12M2.12M-6.24M2.12M13.37M1.64M
Total Non-Current Assets+8.55M10.6M141.74M181.98M772.33M575.64M444.2M316.45M346.77M216.38M
Property, Plant & Equipment4.52M6.92M6.86M8.32M43.84M42.87M43.94M37.24M19.36M15.13M
Fixed Asset Turnover2.60x0.64x0.09x1.97x0.20x0.19x0.23x0.06x0.17x0.32x
Goodwill0000000000
Intangible Assets3.87M3.52M3.31M3.08M625K899K987K831K906K601K
Long-Term Investments-179.68M-219.32M14.33M35.93M695.46M531.86M398.46M60.81M325.63M200.17M
Other Non-Current Assets57K65K117.1M134.2M32.27M531.87M399.27M278.38M879K476K
Total Assets+326.75M298.75M339.85M441.76M941.18M989.99M946.01M702.65M693.97M602.63M
Asset Turnover0.04x0.01x0.00x0.04x0.01x0.01x0.01x0.00x0.00x0.01x
Asset Growth %0.43%-0.09%0.14%0.3%1.13%0.05%-0.04%-0.26%-0.01%-0.13%
Total Current Liabilities+160.52M204.08M273.86M265.76M139.2M180.92M226.13M96.89M51.37M41.39M
Accounts Payable2.39M2.08M3.39M4.64M11.1M8.87M11.35M26.5M14.64M5.52M
Days Payables Outstanding1.18K482.8717.4421.947.19-37.4863.461.08K-
Short-Term Debt4.96M6.95M7.46M12.01M1.46M26.45M5.5M7.5M3.7M4.11M
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K1000K1000K-1000K0
Other Current Liabilities61.29M97.62M121.04M207.08M92.45M-529K152.01M29.4M29.64M27.18M
Current Ratio1.98x1.41x0.72x0.98x1.21x2.29x2.22x3.99x6.76x9.33x
Quick Ratio1.98x1.42x0.73x0.98x1.21x2.29x2.10x3.99x6.76x9.33x
Cash Conversion Cycle------186.3---
Total Non-Current Liabilities+2.18M2.26M1.99M9.03M151.58M155.53M135.72M58.17M184.37M153.31M
Long-Term Debt000357K014.82M14.26M10.24M00
Capital Lease Obligations00410K357K34.91M32.09M29.04M24.16M18.25M14.67M
Deferred Tax Liabilities004.4M6.43M115.44M108.63M89.77M19.64M52.46M0
Other Non-Current Liabilities1.89M2.06M1.42M876K0-1K2.66M4.13M113.66M138.64M
Total Liabilities162.7M206.34M275.85M274.79M290.78M336.45M361.86M155.06M235.74M194.7M
Total Debt+4.96M6.95M7.46M12.37M39.3M76.62M52.75M46.87M25.34M22.36M
Net Debt-129.8M-56.01M-65.19M-104.68M-93.06M-327.26M-413.68M-102.99M-165.74M-258.28M
Debt / Equity0.03x0.08x0.12x0.07x0.06x0.12x0.09x0.09x0.06x0.05x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-10.03x-10.86x-11.30x-7.03x-33.01x-40.57x-31.88x-50.04x-10.84x-13.56x
Total Equity+164.05M92.41M64M166.97M650.4M653.54M584.15M547.59M458.23M407.93M
Equity Growth %0.23%-0.44%-0.31%1.61%2.9%0%-0.11%-0.06%-0.16%-0.11%
Book Value per Share8.854.032.686.1022.2922.3220.3819.2316.5815.13
Total Shareholders' Equity226.12M177.67M214.3M275.51M668.04M669.75M593.51M542.22M464.07M414.71M
Common Stock4.52M4.61M4.68M5.38M5.41M5.42M5.44M5.46M5.46M4.86M
Retained Earnings-111.42M-160.34M-127.87M-167.69M254.44M260.43M199.87M149.52M83.82M32.49M
Treasury Stock0000000-26.49M-44.63M-46.86M
Accumulated OCI-1.05M-2.24M-3.88M-6.07M-18.28M-23.58M-39.61M-14.39M129.15M133.96M
Minority Interest-62.07M-85.25M-150.31M-108.53M-17.64M-16.21M-9.37M5.37M-5.83M-6.77M

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-28.61M-58.03M-88.69M-72.8M-98.16M-131.83M-158.27M-178.79M-105.92M-134.37M
Operating CF Margin %-2.44%-13.1%-136.44%-4.45%-11.3%-15.8%-15.86%-85.55%-31.81%-27.83%
Operating CF Growth %-1.71%-1.03%-0.53%0.18%-0.35%-0.34%-0.2%-0.13%0.41%-0.27%
Net Income-58.24M-81.61M-70.7M-70.66M366.06M4.57M-62.71M-37.06M-65.7M27.78M
Depreciation & Amortization740K1.57M2.1M2.78M6.67M6.64M7.29M8.89M4.93M3.57M
Stock-Based Compensation11.1M10.15M11.85M12.64M14.47M10.72M13.95M14.7M4.42M22.85M
Deferred Taxes-383K-783K-116.81M-19.42M-546.61M-151.35M-112.61M-70.12M00
Other Non-Cash Items13.37M10.7M81.9M-8.1M46.23M6.11M-5.05M-111.12M-67.09M-178.34M
Working Capital Changes4.81M1.94M2.97M9.96M15.03M-8.53M861K15.92M17.52M-10.24M
Change in Receivables1.11M581K-1.67M467K747K-529K-617K-7.73M9.75M629K
Change in Inventory000000-103K000
Change in Payables4.32M3.52M5.24M5.09M11.17M605K8.34M22.03M3.84M-9.7M
Cash from Investing+-184.24M-43.23M83.68M-39.65M63.66M364.48M197.38M-107.22M68.99M240.89M
Capital Expenditures-4.61M-3.68M-2.17M-4.49M-12.54M-5.42M-5.66M-2.18M-245K-11K
CapEx % of Revenue0.39%0.83%3.34%0.27%1.44%0.65%0.57%1.04%0.07%0%
Acquisitions----------
Investments----------
Other Investing-1.16M-39.55M-16.34M125K191K350K-14.91M416K865K255K
Cash from Financing+285.94M29.49M14.7M156.89M49.91M38.87M22.73M-29.83M78.14M-16.96M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid00-91K-8K-112K00000
Share Repurchases----------
Other Financing284.46M27.16M0150.96M-1.68M-2.91M33.84M-4.07M99.98M93.1M
Net Change in Cash----------
Free Cash Flow+-33.22M-61.71M-90.86M-77.29M-110.69M-137.25M-163.94M-180.97M-106.16M-134.38M
FCF Margin %-2.83%-13.93%-139.78%-4.72%-12.74%-16.45%-16.43%-86.59%-31.88%-27.83%
FCF Growth %-2.03%-0.86%-0.47%0.15%-0.43%-0.24%-0.19%-0.1%0.41%-0.27%
FCF per Share-1.79-2.69-3.80-2.82-3.79-4.69-5.72-6.36-3.84-4.98
FCF Conversion (FCF/Net Income)0.73x1.19x-2.87x1.67x-0.23x-22.03x2.61x3.55x1.61x-2.51x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-26.46%-38.05%39.47%-37.8%103.05%0.92%-9.79%-8.9%-13.06%12.36%
Return on Invested Capital (ROIC)-95.55%-156.94%-491.73%-255.4%-32.78%-20.29%-45.31%-48.18%-29.75%-46.17%
Gross Margin93.7%64.57%-10828.46%-372.8%-888.12%100%-1007.03%-6546.17%-48.14%26.04%
Net Margin-335.55%-1101.15%4749.08%-266.65%4847.42%71.75%-606.85%-2409.33%-1972.88%1108.33%
Debt / Equity0.03x0.08x0.12x0.07x0.06x0.12x0.09x0.09x0.06x0.05x
Interest Coverage-10.03x-10.86x-11.30x-7.03x-33.01x-40.57x-31.88x-50.04x-10.84x-13.56x
FCF Conversion0.73x1.19x-2.87x1.67x-0.23x-22.03x2.61x3.55x1.61x-2.51x
Revenue Growth483.5%-62.26%-85.33%2418.62%-46.93%-3.99%19.64%-79.06%59.33%44.98%

Frequently Asked Questions

Valuation & Price

PureTech Health plc (PRTC) has a price-to-earnings (P/E) ratio of 9.5x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

PureTech Health plc (PRTC) reported $6.3M in revenue for fiscal year 2024. This represents a 20% decrease from $7.9M in 2012.

PureTech Health plc (PRTC) grew revenue by 45.0% over the past year. This is strong growth.

PureTech Health plc (PRTC) reported a net loss of $31.5M for fiscal year 2024.

Dividend & Returns

PureTech Health plc (PRTC) has a return on equity (ROE) of 12.4%. This is reasonable for most industries.

PureTech Health plc (PRTC) had negative free cash flow of $220.4M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.